TACCONELLI, Stefania
 Distribuzione geografica
Continente #
EU - Europa 2.916
NA - Nord America 2.800
AS - Asia 1.038
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 4
OC - Oceania 3
Totale 6.774
Nazione #
US - Stati Uniti d'America 2.795
CN - Cina 592
IE - Irlanda 526
UA - Ucraina 526
IT - Italia 382
GB - Regno Unito 367
SE - Svezia 352
TR - Turchia 341
FR - Francia 307
DE - Germania 152
FI - Finlandia 106
PL - Polonia 100
IN - India 78
BE - Belgio 56
RU - Federazione Russa 21
VN - Vietnam 9
IR - Iran 7
EU - Europa 5
NL - Olanda 5
ZA - Sudafrica 5
BR - Brasile 4
BY - Bielorussia 4
AE - Emirati Arabi Uniti 3
GR - Grecia 3
IL - Israele 3
JP - Giappone 3
AT - Austria 2
AU - Australia 2
CA - Canada 2
CZ - Repubblica Ceca 2
MX - Messico 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
CG - Congo 1
CH - Svizzera 1
EE - Estonia 1
EG - Egitto 1
ES - Italia 1
GT - Guatemala 1
ID - Indonesia 1
NZ - Nuova Zelanda 1
Totale 6.774
Città #
Chandler 662
Jacksonville 583
Dublin 517
Southend 312
Princeton 220
Dearborn 182
Izmir 170
Nanjing 155
Ashburn 108
Beijing 105
Wilmington 101
Kraków 98
Cambridge 95
Chieti 82
Altamura 79
Ann Arbor 67
Nanchang 63
Brussels 53
Shenyang 42
Boardman 39
Woodbridge 38
Hebei 29
Changsha 27
Grevenbroich 27
Jiaxing 23
Tianjin 22
Kocaeli 21
Washington 21
Kunming 20
New York 18
Orange 17
Seattle 17
Hangzhou 16
Norwalk 15
Helsinki 14
Spoltore 14
Düsseldorf 11
Hefei 11
Jinan 11
Leawood 11
Lanzhou 10
Shanghai 10
Dong Ket 9
Augusta 8
Houston 8
Montesilvano 8
Guangzhou 7
Menlo Park 7
Fuzhou 6
Ningbo 6
San Mateo 6
Simi Valley 6
Auburn Hills 5
Cape Town 5
L’Aquila 5
Perm 5
Taizhou 5
Tavagnacco 5
Changchun 4
Los Angeles 4
Mogilev 4
Mumbai 4
Rome 4
São Paulo 4
Tappahannock 4
Zhengzhou 4
Ardabil 3
Bari 3
Dubai 3
Glasgow 3
Sagamino 3
San Giovanni Teatino 3
Walnut 3
Amsterdam 2
Ankara 2
Antalya 2
Anzano Del Parco 2
Avezzano 2
Brno 2
Bruges 2
Caravaggio 2
Clearwater 2
Ferrara 2
Fiano Romano 2
Grafing 2
Hanover 2
Kish 2
Lanciano 2
Liverpool 2
Mexico City 2
Monmouth Junction 2
Osimo 2
Padova 2
Paternò 2
Pescara 2
San Vito Chietino 2
Senigallia 2
Toronto 2
Vendelso 2
Verona 2
Totale 4.344
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 174
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 118
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 104
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 102
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 94
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 93
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 93
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 90
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 90
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 87
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 87
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 87
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 86
Oxidative stress and platelet activation in essential hyperytension 85
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 85
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 83
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 83
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 81
Pharmacodynamic of cyclooxygenase inhibitors in humans. 80
Platelet activation in patients with colorectal cancer. 80
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 79
Antithrombotic Agents and Cancer 79
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 79
New insights into COX-2 biology and inhibition. 78
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 78
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 78
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 77
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 76
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 76
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 74
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 72
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 72
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 72
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 71
Mechanistic and pharmacological issues of aspirin as an anticancer agent 70
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 69
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 69
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 69
P2Y12 Receptors in Tumorigenesis and Metastasis 69
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 68
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 67
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 67
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 67
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 67
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 67
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 66
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 66
Clinical pharmacology of selective COX-2 inhibitors. 66
Human pharmacology of naproxen sodium. 66
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 65
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 65
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 65
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 64
NSAIDs and cardiovascular disease. 64
Clinical pharmacology of novel selective COX-2 inhibitors. 63
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 63
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 62
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 62
Gut microbiota, host gene expression, and aging. 61
Risk management profile of etoricoxib: An example of personalized medicine 61
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 60
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 60
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 60
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 59
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 59
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 58
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 58
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 58
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 58
Clinical pharmacology of etoricoxib. 58
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 58
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 58
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. 57
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 57
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 56
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 55
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 54
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 54
Determinants of platelet activation in human essential hypertension. 54
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 53
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 52
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 52
Parmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 52
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 51
Mode of action of aspirin as a chemopreventive agent. 51
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. 51
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 50
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 50
Isoprostanes and other markers of peroxidation in atherosclerosis. 50
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 50
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 49
Platelets induce free and phospholipid-esterified 12-hydroxyeicosatetraenoic acid generation in colon cancer cells by delivering 12-lipoxygenase 48
Oxidative Damage, Platelet Activation, and Inflammation to Predict Mobility Disability and Mortality in Older Persons: Results From the Health Aging and Body Composition Study. 47
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 46
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 46
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 45
HETEROGENEITY IN THE SUPPRESSION OF PLATELET CYCLOOXYGENASE-1 ACTIVITY BY ASPIRIN IN CARDIOVASCULAR DESEASE. 44
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. 44
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 43
Correlazione tra aumentata secrezione di cortisolo e marker di infiammazione nei pazienti con sindromi coronariche acute 42
Totale 6.758
Categoria #
all - tutte 23.138
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.138


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019270 0 0 0 0 0 0 0 0 2 12 9 247
2019/20201.342 406 95 4 61 89 114 188 148 30 76 122 9
2020/2021752 110 2 107 8 69 129 29 23 51 124 47 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.763 124 220 78 223 165 347 121 139 232 24 30 60
2023/2024708 54 46 71 27 75 225 183 23 4 0 0 0
Totale 7.181